Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Disease, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
Á¦9Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - Áúȯº°
°³¿ä
Áúȯº° ºÎ¹® Á¡À¯À² ºÐ¼®
¾Ï
À¯Àü¼º Áúȯ
°¨¿°Áõ
±âŸ
Á¦10Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ¿ëµµº°
°³¿ä
¿ëµµº° ºÎ¹® Á¡À¯À² ºÐ¼®
¾ÈƼ¼¾½º ¹× RNAi ¿ä¹ý
À¯ÀüÀÚ Ä¡·á
¼¼Æ÷Ä¡·á
¹é½ÅÇÐ
Á¶»ç
Á¦11Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°
°³¿ä
ÃÖÁ¾»ç¿ëÀÚº° ºÎ¹® Á¡À¯À² ºÐ¼®
Á¦¾à ¹× ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Á¶»ç±â°ü
Á¦12Àå ¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - Áö¿ªº°
¼·Ð
ºÏ¹Ì
°³¿ä
ºÏ¹ÌÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
¹Ì±¹
ij³ª´Ù
À¯·´
°³¿ä
À¯·´ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
µ¶ÀÏ
ÀÌÅ»¸®¾Æ
¿µ±¹
ÇÁ¶û½º
·¯½Ã¾Æ
³×´ú¶õµå
½º¿þµ§
Æú¶õµå
±âŸ
¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
°³¿ä
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
Àεµ
Áß±¹
ÀϺ»
Çѱ¹
È£ÁÖ
ű¹
Àεµ³×½Ã¾Æ
Çʸ®ÇÉ
±âŸ
¶óƾ¾Æ¸Þ¸®Ä«
°³¿ä
¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
ÄÝ·Òºñ¾Æ
±âŸ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°³¿ä
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ¿ä Á¦Á¶¾÷ü
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
À̽º¶ó¿¤
ÅÍŰ
¾ËÁ¦¸®
ÀÌÁýÆ®
±âŸ
Á¦13Àå ÁÖ¿ä º¥´õ ºÐ¼®-¹ÙÀÌ·¯½º º¤ÅÍ ¹× Çö󽺹̵å DNA Á¦Á¶¾÷°è
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä
Merck KGaA
Lonza
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent Inc.
Wuxi Biologics
Takara Bio Inc.
Waisman Biomanufacturing
Genezen laboratories
Batavia Biosciences
Miltenyi Biotec GmbH
SIRION Biotech GmbH
Virovek Incorporation
Others
Á¦14Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á
LSH
¿µ¹® ¸ñÂ÷
¿µ¹®¸ñÂ÷
REPORT HIGHLIGHT
Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,673.98 Million in 2023, expanding at a CAGR of 19.61% from 2024 to 2032.
The Viral Vector and Plasmid DNA Manufacturing sector represents a vital segment within the biopharmaceutical industry, dedicated to producing viral vectors and plasmid DNA for gene therapy and vaccine development purposes. Viral vectors are genetically engineered viruses used to transport therapeutic genes into target cells, while plasmid DNA serves as a critical component in gene therapy and DNA vaccine production. This market significantly contributes to advancing medical treatments by facilitating the development of innovative therapies for a broad spectrum of genetic disorders, infectious diseases, and cancers. Given the rapid progress in biotechnology and the increasing investment in gene therapy research, the demand for viral vectors and plasmid DNA manufacturing continues to steadily rise. This growth is fueled by factors such as the increasing prevalence of genetic diseases, the expanding pipeline of gene therapy candidates, and the growing adoption of personalized medicine approaches.
Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics
Advancements in gene therapy to propel market demand
The primary drivers of the market include advancements in gene therapy, as the development of new gene therapies heavily relies on high-quality viral vectors and plasmid DNA. Moreover, enhancements in manufacturing processes have enabled more efficient production of viral vectors and plasmid DNA at larger scales, leading to cost reductions and improved overall quality. With increased investments in the cell and gene therapy research space, there is significant demand for viral vectors in the market. Consequently, various organizations are providing funds to accelerate developments in manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada granted USD 1.89 million to a consortium led by iVexSol Canada for the development of an advanced manufacturing process for lentiviral vectors. iVexSol Canada, a vector manufacturing company, has collaborated with several entities to develop an advanced LVV manufacturing platform.
Viral Vector and Plasmid DNA Manufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.81% over the forecast period (2024-2032)
Based on Vector Type segmentation, adeno-associated virus was predicted to show maximum market share in the year 2023
Based on Workflow segmentation, downstream processing was the leading type in 2023
Based on Disease segmentation, Cancer was the leading type in 2023
Based on end user segmentation, research institute was the leading type in 2023
Based on Application segmentation, Antisense & RNAi Therapy was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:
The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented on the basis of Vector Type, Workflow, Disease, Application, End User and Region.
The market is divided into six categories based on vector type: Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others. In terms of vector type, the adeno-associated virus (AAV) segment led the market with the largest revenue share in 2023. AAVs are in high demand, with their utilization in clinical trials increasing rapidly due to their precision in delivering genes to the region of interest. This rising adoption is attributed to clinical trials related to the development of orthopedic and ocular gene therapies demonstrating increased efficiency and efficacy. An article published in Springer in August 2022 stated that AAV-mediated gene therapy could prevent acquired hearing loss, further highlighting the expanding applications of AAV across various therapeutic areas.
The market is divided into two categories based on Workflow: Upstream Manufacturing and Downstream Manufacturing. Based on the workflow, the downstream processing segment dominated the market in 2023 with the largest revenue share, owing to highly complex procedures involved in polishing and purifying clinical-grade final products. With the growing demand for clinical-grade viral vectors, manufacturers are actively engaged in developing novel, cost-effective downstream processes to address challenges associated with conventional lab-scale vector manufacturing. This approach is expected to support market growth, as seen in examples such as combining fed-batch fermentation techniques and genetically optimized cell systems with conventional and novel purification technologies.
Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:
In the dynamic landscape of the Viral Vector and Plasmid DNA Manufacturing market, companies implement diverse strategies to uphold competitiveness and address the evolving demands of the biopharmaceutical industry. Collaboration and strategic partnerships play a crucial role in driving innovation, expanding capabilities, and accessing complementary expertise and resources. Companies frequently establish strategic alliances with biopharmaceutical firms, academic institutions, and contract development and manufacturing organizations (CDMOs) to co-develop gene therapy products, exchange research insights, and utilize manufacturing infrastructure. Moreover, investments in research and development (R&D) are essential for advancing manufacturing technologies, enhancing process efficiency, and improving product quality and scalability. Continuous innovation in upstream and downstream processing techniques, purification methods, and analytical technologies is vital for optimizing viral vector and plasmid DNA production processes. Additionally, ensuring regulatory compliance and adhering to Good Manufacturing Practices (GMP) standards are imperative for maintaining product quality, safety, and efficacy throughout the manufacturing lifecycle.
Recent Developments:
In October 2023, AGC Biologics revealed plans for the expansion of their plasmid DNA (pDNA) manufacturing facility located in Germany. This strategic move is anticipated to enable the company to decrease manufacturing time.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Merck KGaA
Lonza
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent Inc.
Wuxi Biologics
Takara Bio Inc.
Waisman Biomanufacturing
Genezen laboratories
Batavia Biosciences
Miltenyi Biotec GmbH
SIRION Biotech GmbH
Virovek Incorporation
Others
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032
Adenovirus
Retrovirus
Adeno-Associated Virus (AAV)
Lentivirus
Plasmids
Others
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032
Upstream Manufacturing
Downstream Manufacturing
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032
Cancer
Genetic Disorders
Infectious Diseases
Others
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
Antisense & RNAi Therapy
Gene Therapy
Cell Therapy
Vaccinology
Research Applications
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1.Viral Vector and Plasmid DNA Manufacturing Market Overview
1.1.Study Scope
1.2.Market Estimation Years
2.Executive Summary
2.1.Market Snippet
2.1.1.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
2.1.2.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
2.1.3.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Disease
2.1.4.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
2.1.5.Viral Vector and Plasmid DNA Manufacturing Market Snippet by End User
2.1.6.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
2.1.7.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
2.2.Competitive Insights
3.Viral Vector and Plasmid DNA Manufacturing Key Market Trends
3.1.Viral Vector and Plasmid DNA Manufacturing Market Drivers
3.1.1.Impact Analysis of Market Drivers
3.2.Viral Vector and Plasmid DNA Manufacturing Market Restraints
3.2.1.Impact Analysis of Market Restraints
3.3.Viral Vector and Plasmid DNA Manufacturing Market Opportunities
3.4.Viral Vector and Plasmid DNA Manufacturing Market Future Trends
4.Viral Vector and Plasmid DNA Manufacturing Industry Study
4.1.PEST Analysis
4.2.Porter's Five Forces Analysis
4.3.Growth Prospect Mapping
4.4.Regulatory Framework Analysis
5.Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis
5.1.Pre-COVID-19 Impact Analysis
5.2.Post-COVID-19 Impact Analysis
5.2.1.Top Performing Segments
5.2.2.Marginal Growth Segments
5.2.3.Top Looser Segments
5.2.4.Marginal Loss Segments
6.Viral Vector and Plasmid DNA Manufacturing Market Landscape
6.1.Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
6.2.Breakdown Data, by Key Manufacturer
6.2.1.Established Players' Analysis
6.2.2.Emerging Players' Analysis
7.Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type
7.1.Overview
7.1.1.Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
7.1.2.Adenovirus
7.1.3.Retrovirus
7.1.4.Adeno-Associated Virus (AAV)
7.1.5.Lentivirus
7.1.6.Plasmids
7.1.7.Others
8.Viral Vector and Plasmid DNA Manufacturing Market - By Workflow
8.1.Overview
8.1.1.Segment Share Analysis, By Workflow, 2023 & 2032 (%)
8.1.2.Upstream Manufacturing
8.1.3.Downstream Manufacturing
9.Viral Vector and Plasmid DNA Manufacturing Market - By Disease
9.1.Overview
9.1.1.Segment Share Analysis, By Disease, 2023 & 2032 (%)
9.1.2.Cancer
9.1.3.Genetic Disorders
9.1.4.Infectious Diseases
9.1.5.Others
10.Viral Vector and Plasmid DNA Manufacturing Market - By Application
10.1.Overview
10.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
10.1.2.Antisense & RNAi Therapy
10.1.3.Gene Therapy
10.1.4.Cell Therapy
10.1.5.Vaccinology
10.1.6.Research Applications
11.Viral Vector and Plasmid DNA Manufacturing Market - By End User
11.1.Overview
11.1.1.Segment Share Analysis, By End User, 2023 & 2032 (%)
11.1.2.Pharmaceutical and Biopharmaceutical Companies
11.1.3.Research Institutes
12.Viral Vector and Plasmid DNA Manufacturing Market- By Geography
12.1.Introduction
12.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2.North America
12.2.1.Overview
12.2.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
12.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4.North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
12.2.5.North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
12.2.6.North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
12.2.7.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.8.North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)